Terms ending in 2037
Every in-force patent on Precision Biosciences, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,278,632 | Engineered Nucleases Useful for Treatment of Hemophilia A In force · High confidence | Precision BioSciences, Inc. | In force | High confidence | |
| US 10,800,833 | Co-Stimulatory Domains for Use in Genetically-Modified Cells In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,286,291 | Co-Stimulatory Domains for Use in Genetically-Modified Cells In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 10,662,416 | Engineered Meganucleases Specific for Recognition Sequences in the Hepatitis B Virus Genome In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 10,851,358 | Engineered Meganucleases Specific for Recognition Sequences in the Hepatitis B Virus Genome In force · Medium confidence | Precision Biosciences, Inc. | In force | Medium confidence | |
| US 11,274,285 | Engineered Meganucleases Specific for Recognition Sequences in the Hepatitis B Virus Genome In force · High confidence | Precision Biosciences, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.